PNH drug safety study ends early: what happened?
NCT ID NCT05741346
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This study aimed to monitor the long-term safety of BCX9930 in people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants who continued taking BCX9930 because they had no other good treatment options. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Paris, France
-
Investigative Site
Budapest, Hungary
-
Investigative Site
Ampang, Malaysia
-
Investigative Site
Bloemfontein, South Africa
-
Investigative Site
Cape Town, South Africa
-
Investigative Site
Pretoria, South Africa
-
Investigative Site
Daejeon, South Korea
-
Investigative Site
Barcelona, Spain
-
Investigative Site
Valencia, Spain
-
Investigative Site
Leeds, United Kingdom
-
Investigative Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.